Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
| Price | $34.53 |
|---|---|
| Market cap | $890.01M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 7.45-42.143 |
| Beta | -0.28 |
Explore FTH's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.